Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Key Takeaway: Viridian Therapeutics has announced proposed concurrent public offerings of convertible senior notes due 2032, common stock, and Series B non-voting convertible preferred stock. This move is part of their strategy to raise capital. Further details regarding the offerings have not been disclosed.